Literature DB >> 18550106

The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.

Athanase Billis1, Marbele S Guimaraes, Leandro L L Freitas, Luciana Meirelles, Luis A Magna, Ubirajara Ferreira.   

Abstract

PURPOSE: At an International Society of Urological Pathology consensus conference in 2005 the Gleason grading system for prostatic carcinoma underwent its first major revision. We compared the concordance of pattern and change of prognostic groups for the conventional and the modified Gleason grading, and checked the discriminative power of the modified Gleason grading.
MATERIALS AND METHODS: The grading was based on 172 prostatic needle biopsies of patients subsequently undergoing radical prostatectomy. Four prognostic Gleason grading groups were considered, divided into scores of 2-4, 5-6, 7 and 8-10. To check the discriminative power of the modified Gleason grading we compared the time of biochemical (prostate specific antigen) progression-free outcome according to prognostic groups between standard and revised grading.
RESULTS: The greatest impact of the International Society of Urological Pathology consensus recommendations for Gleason grading was seen on the secondary pattern which had the lowest percentage of concordance and was reflected in a change toward higher Gleason prognostic groups. Of 172 patients in whom the Gleason prognostic group was changed (to higher grades) based solely on the consensus criteria, 46 (26.7%) had higher preoperative prostate specific antigen, more extensive tumors and positive surgical margins, and higher pathological stage. The revised Gleason grading identified in this series a higher number of patients in the aggressive prognostic group Gleason score 8-10 who had a significantly shorter time to biochemical progression-free outcome after radical prostatectomy (log rank p = 0.011).
CONCLUSIONS: The findings of this study indicate that the recommendations of the International Society of Urological Pathology are a valuable refinement of the standard Gleason grading system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18550106     DOI: 10.1016/j.juro.2008.04.018

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  37 in total

1.  Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study.

Authors:  Sabine Brookman-May; Matthias May; Wolf-Ferdinand Wieland; Steffen Lebentrau; Sven Gunia; Stefan Koch; Christian Gilfrich; Jan Roigas; Bernd Hoschke; Maximilian Burger
Journal:  World J Urol       Date:  2010-12-30       Impact factor: 4.226

2.  [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.

Authors:  Brian V Le; Christopher R Griffin; Stacy Loeb; Gustavo F Carvalhal; Donghui Kan; Nikola A Baumann; William J Catalona
Journal:  J Urol       Date:  2010-02-19       Impact factor: 7.450

3.  Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?

Authors:  Hillary M Ross; Oleksandr N Kryvenko; Janet E Cowan; Jeffry P Simko; Thomas M Wheeler; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2012-09       Impact factor: 6.394

4.  Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading.

Authors:  Lars Egevad; Ferran Algaba; Daniel M Berney; Liliane Boccon-Gibod; Eva Compérat; Andrew J Evans; Rainer Grobholz; Glen Kristiansen; Cord Langner; Gina Lockwood; Antonio Lopez-Beltran; Rodolfo Montironi; Pedro Oliveira; Matthias Schwenkglenks; Ben Vainer; Murali Varma; Vincent Verger; Philippe Camparo
Journal:  Virchows Arch       Date:  2011-06-23       Impact factor: 4.064

Review 5.  Current perspectives on Gleason grading of prostate cancer.

Authors:  Kenneth A Iczkowski; M Scott Lucia
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

Review 6.  Gleason 6 Prostate Cancer: Translating Biology into Population Health.

Authors:  Scott E Eggener; Ketan Badani; Daniel A Barocas; Glen W Barrisford; Jed-Sian Cheng; Arnold I Chin; Anthony Corcoran; Jonathan I Epstein; Arvin K George; Gopal N Gupta; Matthew H Hayn; Eric C Kauffman; Brian Lane; Michael A Liss; Moben Mirza; Todd M Morgan; Kelvin Moses; Kenneth G Nepple; Mark A Preston; Soroush Rais-Bahrami; Matthew J Resnick; M Minhaj Siddiqui; Jonathan Silberstein; Eric A Singer; Geoffrey A Sonn; Preston Sprenkle; Kelly L Stratton; Jennifer Taylor; Jeffrey Tomaszewski; Matt Tollefson; Andrew Vickers; Wesley M White; William T Lowrance
Journal:  J Urol       Date:  2015-04-04       Impact factor: 7.450

Review 7.  One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading.

Authors:  John R Srigley; Brett Delahunt; Lars Egevad; Hemamali Samaratunga; John Yaxley; Andrew J Evans
Journal:  Can Urol Assoc J       Date:  2016 Sep-Oct       Impact factor: 1.862

8.  The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era.

Authors:  Stavros Sfoungaristos; Ioannis Katafigiotis; Petros Perimenis
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

9.  The value of the 2005 International Society of Urological Pathology (ISUP) modified Gleason grading system as a predictor of biochemical recurrence after radical prostatectomy.

Authors:  Athanase Billis; Maisa M Q Quintal; Luciana Meirelles; Leandro L L Freitas; Larissa B E Costa; João F L Bonfitto; Betina L Diniz; Paola H Poletto; Luís A Magna; Ubirajara Ferreira
Journal:  Int Urol Nephrol       Date:  2013-10-06       Impact factor: 2.370

10.  The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses.

Authors:  Neerav Monga; Amyn Sayani; Daniel A Rubinger; Timothy H Wilson; Zhen Su
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.